Hanmi Science Pursues Global Expansion of Surgical Hemostatic Agents
Hanmi Science, the holding company of Hanmi Group, is actively expanding its medical device business with a focus on international markets. The company announced its participation in MEDICA 2025,a leading global medical device exhibition held in Düsseldorf,Germany from November 17th to 20th,as a key step in this strategy.
At the expo,Hanmi Science will showcase three surgical hemostatic agents developed by Terracion Biomedical,a biosurgery specialist,for which Hanmi Science holds overseas sales rights. these products – Wuzfix, Tablowax, and Acticlat - represent a core component of Hanmi ScienceS medical device portfolio.
Wuzfix is an absorbable powder designed to control bleeding from exudative areas following initial hemostasis during surgery. Tablowax is an absorbable hemostatic agent based on poloxamer, forming a protective film on bone surfaces to maintain sealing, and is applicable in thoracic, orthopedic, and neurosurgery procedures. Acticlat is an active hemostatic agent combining thrombin within a starch-derived polymer matrix, delivered via a prefilled syringe for ease of use. It is designed to decompose within three days, minimizing potential inflammation or foreign body reactions.
Hanmi Science highlights Acticlat’s competitive advantage due to its formulation excluding animal-derived ingredients, its use of safe, starch-based materials, and its rapid hemostatic capabilities.The company is responsible for both domestic distribution and international export of these products.
Through MEDICA 2025, Hanmi Science intends to establish partnerships with distributors and hospital representatives in key regions including Europe, the Middle East, and Asia. The company aims to demonstrate the clinical benefits and technological advancements of its hemostatic agents to potential partners.
A representative from hanmi Science’s Medical Device Division stated that participation in MEDICA 2025 is a meaningful opportunity to promote Korean medical technology globally and to strengthen the company’s position within the international healthcare market.
This expansion of the medical device business is part of Hanmi Science’s broader strategy to build an integrated healthcare portfolio encompassing cosmetics,health functional foods,consumer health platforms,and pharmaceutical-based derma cosmetics under the ‘Pro-Calm’ brand.
